Search

Your search keyword '"Maloney, Susan"' showing total 619 results
Start Over Author "Maloney, Susan"
619 results on '"Maloney, Susan"'

1. Collect Once, Use Many Times: Attaining Unified Metrics for Tuberculosis Preventive Treatment for People Living With HIV

Author

Fukunaga, Rena, Lowrance, David, MacNeil, Adam, Al-Samarrai, Teeb, Cavanaugh, Joseph, Baddeley, Annabel, Nichols, Catherine, Peterson, Meaghan, Ahmedov, Sevim, Singh, Vindi, Edwards, Celeste Gracia, Jain, Suman, Date, Anand, and Maloney, Susan A

Subjects
Public aspects of medicine, RA1-1270
Abstract

The World Health Organization (WHO) recommends providing tuberculosis preventive treatment (TPT) to all persons living with HIV and to all household contacts of persons with bacteriologically confirmed pulmonary tuberculosis disease. Regrettably, the absence of a harmonized data collection and management approach to TPT indicators has contributed to programmatic challenges at local, national, and global levels. However, in April 2020, the WHO launched the Consolidated HIV Strategic Information Guidelines, with an updated set of priority indicators. These guidelines recommend that Ministries of Health collect, report, and use data on TPT completion in addition to TPT initiation. Both indicators are reflected in the WHO’s list of 15 core indicators for program management and are also required by the US President’s Emergency Plan for AIDS Relief’s Monitoring, Evaluation, and Reporting (MER) guidance. Although not perfectly harmonized, both frameworks now share essential indicator characteristics. Aligned indicators are necessary for robust strategic and operational planning, resource allocation, and data communication. “Collect once, use many times” is a best practice for strategic information management. Building harmonized and sustainable health systems will enable countries to successfully maintain essential HIV, tuberculosis, and other health services while combatting new health threats.

Published
2021
Full Text
View/download PDF

4. Can the “female protective effect” liability threshold model explain sex differences in autism spectrum disorder?

Author

Dougherty, Joseph D, Marrus, Natasha, Maloney, Susan E, Yip, Benjamin, Sandin, Sven, Turner, Tychele N, Selmanovic, Din, Kroll, Kristen L, Gutmann, David H, Constantino, John N, and Weiss, Lauren A

Subjects
Intellectual and Developmental Disabilities (IDD), Mental Health, Autism, Brain Disorders, Mental health, Female, Male, Humans, Autism Spectrum Disorder, Sex Characteristics, Phenotype, Penetrance, Neurosciences, Psychology, Cognitive Sciences, Neurology & Neurosurgery
Abstract

Male sex is a strong risk factor for autism spectrum disorder (ASD). The leading theory for a "female protective effect" (FPE) envisions males and females have "differing thresholds" under a "liability threshold model" (DT-LTM). Specifically, this model posits that females require either a greater number or larger magnitude of risk factors (i.e., greater liability) to manifest ASD, which is supported by the finding that a greater proportion of females with ASD have highly penetrant genetic mutations. Herein, we derive testable hypotheses from the DT-LTM for ASD, investigating heritability, familial recurrence, correlation between ASD penetrance and sex ratio, population traits, clinical features, the stability of the sex ratio across diagnostic changes, and highlight other key prerequisites. Our findings reveal that several key predictions of the DT-LTM are not supported by current data, requiring us to establish a different conceptual framework for evaluating alternate models that explain sex differences in ASD.

Published
2022

5. Early Release - Overseas Treatment of Latent Tuberculosis Infection in US–Bound Immigrants - Volume 28, Number 3—March 2022 - Emerging Infectious Diseases journal - CDC

Author

Khan, Amera, Phares, Christina R, Phuong, Hoang Lan, Trinh, Dang Thi Kieu, Phan, Ha, Merrifield, Cindy, Le, Phan Thi Hong, Lien, Quach Thi Kim, Lan, Sooc Ngoc, Thoa, Phan Thi Kim, Thu, Le Tran Minh, Tran, Tiffany, Tran, Cuc, Platt, Lucy, Maloney, Susan A, Nhung, Nguyen Viet, Nahid, Payam, and Oeltmann, John E

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Prevention, Infectious Diseases, Emerging Infectious Diseases, Tuberculosis, Vaccine Related, Rare Diseases, Biodefense, Infection, Good Health and Well Being, Emigrants and Immigrants, Female, Humans, Interferon-gamma Release Tests, Latent Tuberculosis, Prospective Studies, Tuberculin Test, United States, bacteria, bacterial infections, respiratory infections, tuberculosis and other mycobacteria, Medical Microbiology, Public Health and Health Services, Microbiology, Clinical sciences, Epidemiology, Health services and systems
Abstract

Seventy percent of tuberculosis (TB) cases in the United States occur among non-US-born persons; cases usually result from reactivation of latent TB infection (LTBI) likely acquired before the person's US arrival. We conducted a prospective study among US immigrant visa applicants undergoing the required overseas medical examination in Vietnam. Consenting applicants >15 years of age were offered an interferon-γ release assay (IGRA); those 12-14 years of age received an IGRA as part of the required examination. Eligible participants were offered LTBI treatment with 12 doses of weekly isoniazid and rifapentine. Of 5,311 immigrant visa applicants recruited, 2,438 (46%) consented to participate; 2,276 had an IGRA processed, and 484 (21%) tested positive. Among 452 participants eligible for treatment, 304 (67%) initiated treatment, and 268 (88%) completed treatment. We demonstrated that using the overseas medical examination to provide voluntary LTBI testing and treatment should be considered to advance US TB elimination efforts.

Published
2022

7. Distinct disease mutations in DNMT3A result in a spectrum of behavioral, epigenetic, and transcriptional deficits

Author

Beard, Diana C., Zhang, Xiyun, Wu, Dennis Y., Martin, Jenna R., Erickson, Alyssa, Boua, Jane Valeriane, Hamagami, Nicole, Swift, Raylynn G., McCullough, Katherine B., Ge, Xia, Bell-Hensley, Austin, Zheng, Hongjun, Palmer, Cory W., Fuhler, Nicole A., Lawrence, Austin B., Hill, Cheryl A., Papouin, Thomas, Noguchi, Kevin K., McAlinden, Audrey, Garbow, Joel R., Dougherty, Joseph D., Maloney, Susan E., and Gabel, Harrison W.

Published
2023
Full Text
View/download PDF

11. Overseas Treatment of Latent Tuberculosis Infection in US--Bound Immigrants

Author

Khan, Amera, Phares, Christina R., Phuong, Hoang Lan, Trinh, Dang Thi Kieu, Phan, Ha, Merrifield, Cindy, Le, Phan Thi Hong, Lien, Quach Thi Kim, Lan, Sooc Ngoc, Thoa, Phan Thi Kim, Thu, Le Tran Minh, Tran, Tiffany, Tran, Cuc, Platt, Lucy, Maloney, Susan A., Nhung, Nguyen Viet, Nahid, Payam, and Oeltmann, John E.

Subjects
United States -- Health policy, Infection control -- Methods, Interferon gamma release tests -- Usage, Immigrants -- Health aspects, Tuberculosis -- Control -- Demographic aspects, Health
Abstract

In 1989, the US Advisory Council on the Elimination of Tuberculosis declared a goal to eliminate tuberculosis (TB) in the United States by 2010 (1). TB elimination is defined as [...]

Published
2022
Full Text
View/download PDF

13. Mice lacking Astn2 have ASD-like behaviors and altered cerebellar circuit properties.

Author

Hanzel, Michalina, Fernando, Kayla, Maloney, Susan E., Horn, Zachi, Shiaoching Gong, Mätlik, Kärt, Jiajia Zhao, Pasolli, H. Amalia, Heissel, Søren, Dougherty, Joseph D., Hull, Court, and Hatten, Mary E.

Subjects
AUTISM spectrum disorders, PURKINJE cells, MOLECULAR volume, LANGUAGE delay, DENDRITIC spines
Abstract

Astrotactin 2 (ASTN2) is a transmembrane neuronal protein highly expressed in the cerebellum that functions in receptor trafficking and modulates cerebellar Purkinje cell (PC) synaptic activity. Individuals with ASTN2 mutations exhibit neurodevelopmental disorders, including autism spectrum disorder (ASD), attention-deficit/hyperactivity disorder (ADHD), learning difficulties, and language delay. To provide a genetic model for the role of the cerebellum in ASD-related behaviors and study the role of ASTN2 in cerebellar circuit function, we generated global and PC-specific conditional Astn2 knockout (KO and cKO, respectively) mouse lines. Astn2 KO mice exhibit strong ASD-related behavioral phenotypes, including a marked decrease in separation-induced pup ultrasonic vocalization calls, hyperactivity, repetitive behaviors, altered behavior in the three-chamber test, and impaired cerebellar-dependent eyeblink conditioning. Hyperactivity and repetitive behaviors are also prominent in Astn2 cKO animals, but they do not show altered behavior in the three-chamber test. By Golgi staining, Astn2 KO PCs have region-specific changes in dendritic spine density and filopodia numbers. Proteomic analysis of Astn2 KO cerebellum reveals a marked upregulation of ASTN2 family member, ASTN1, a neuron-glial adhesion protein. Immunohistochemistry and electron microscopy demonstrate a significant increase in Bergmann glia volume in the molecular layer of Astn2 KO animals. Electrophysiological experiments indicate a reduced frequency of spontaneous excitatory postsynaptic currents (EPSCs), as well as increased amplitudes of both spontaneous EPSCs and inhibitory postsynaptic currents in the Astn2 KO animals, suggesting that pre-and postsynaptic components of synaptic transmission are altered. Thus, ASTN2 regulates ASD-like behaviors and cerebellar circuit properties. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Pediatric Tuberculosis: A Review of Evidence-Based Best Practices for Clinicians and Health Care Providers.

Author

Moore, Brittany K., Graham, Stephen M., Nandakumar, Subhadra, Doyle, Joshua, and Maloney, Susan A.

Subjects
MEDICAL personnel, RESOURCE-limited settings, BEST practices, TUBERCULOSIS, PEDIATRIC therapy
Abstract

Advances in pediatric TB care are promising, the result of decades of advocacy, operational and clinical trials research, and political will by national and local TB programs in high-burden countries. However, implementation challenges remain in linking policy to practice and scaling up innovations for prevention, diagnosis, and treatment of TB in children, especially in resource-limited settings. There is both need and opportunity to strengthen clinician confidence in making a TB diagnosis and managing the various manifestations of TB in children, which can facilitate the translation of evidence to action and expand access to new tools and strategies to address TB in this population. This review aims to summarize existing guidance and best practices for clinicians and health care providers in low-resource, TB-endemic settings and identify resources with more detailed and actionable information for decision-making along the clinical cascade to prevent, find, and cure TB in children. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. A Proposed General Method for Parameter Estimation of Noise Corrupted Oscillator Systems

Author

OBrien Jr, Francis J., Johnnie, Nathan, Maloney, Susan, and Ross, Aimee

Subjects
Computer Science - Systems and Control, Physics - Data Analysis, Statistics and Probability
Abstract

This paper provides a proposed means to estimate parameters of noise corrupted oscillator systems. An application for a submarine combat control systems (CCS) rack is described as exemplary of the method., Comment: 33 pages, 9 figures

Published
2012

28. A common single nucleotide variant in the cytokine receptor-like factor-3 (CRLF3) gene causes neuronal deficits in human and mouse cells

Author

Wilson, Anna F, primary, Barakat, Rasha, additional, Mu, Rui, additional, Karush, Leah L, additional, Gao, Yunqing, additional, Hartigan, Kelly A, additional, Chen, Ji-Kang, additional, Shu, Hongjin, additional, Turner, Tychele N, additional, Maloney, Susan E, additional, Mennerick, Steven J, additional, Gutmann, David H, additional, and Anastasaki, Corina, additional

Published
2023
Full Text
View/download PDF

30. Colonization Density of the Upper Respiratory Tract as a Predictor of Pneumonia—Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, and Pneumocystis jirovecii

Author

PERCH Study Group, Park, Daniel E., Baggett, Henry C., Howie, Stephen R. C., Shi, Qiyuan, Watson, Nora L., Brooks, W. Abdullah, Knoll, Maria Deloria, Hammitt, Laura L., Kotloff, Karen L., Levine, Orin S., Madhi, Shabir A., Murdoch, David R., O'Brien, Katherine L., Scott, J. Anthony G., Thea, Donald M., Ahmed, Dilruba, Antonio, Martin, Baillie, Vicky L., DeLuca, Andrea N., Driscoll, Amanda J., Fu, Wei, Gitahi, Caroline W., Olutunde, Emmanuel, Higdon, Melissa M., Hossain, Lokman, Karron, Ruth A., Maiga, Abdoul Aziz, Maloney, Susan A., Moore, David P., Morpeth, Susan C., Mwaba, John, Mwenechanya, Musaku, Prosperi, Christine, Sylla, Mamadou, Thamthitiwat, Somsak, Zeger, Scott L., and Feikin, Daniel R.

Published
2017

31. Extensive characterization of a Williams syndrome murine model shows Gtf2ird1‐mediated rescue of select sensorimotor tasks, but no effect on enhanced social behavior

Author

Nygaard, Kayla R., primary, Maloney, Susan E., additional, Swift, Raylynn G., additional, McCullough, Katherine B., additional, Wagner, Rachael E., additional, Fass, Stuart B., additional, Garbett, Krassimira, additional, Mirnics, Karoly, additional, Veenstra‐VanderWeele, Jeremy, additional, and Dougherty, Joseph D., additional

Published
2023
Full Text
View/download PDF

32. Pertussis-Associated Pneumonia in Infants and Children From Low- and Middle-Income Countries Participating in the PERCH Study

Author

Pneumonia Etiology Research for Child Health (PERCH) Study Group, Barger-Kamate, Breanna, Knoll, Maria Deloria, Kagucia, E. Wangeci, Prosperi, Christine, Baggett, Henry C., Brooks, W. Abdullah, Feikin, Daniel R., Hammitt, Laura L., Howie, Stephen R. C., Levine, Orin S., Madhi, Shabir A., Scott, J. Anthony G., Thea, Donald M., Amornintapichet, Tussanee, Anderson, Trevor P., Awori, Juliet O., Baillie, Vicky L., Chipeta, James, DeLuca, Andrea N., Driscoll, Amanda J., Goswami, Doli, Higdon, Melissa M., Hossain, Lokman, Karron, Ruth A., Maloney, Susan, Moore, David P., Morpeth, Susan C., Mwananyanda, Lawrence, Ofordile, Ogochukwu, Olutunde, Emmanuel, Park, Daniel E., Sow, Samba O., Tapia, Milagritos D., Murdoch, David R., O'Brien, Katherine L., and Kotloff, Karen L.

Published
2016

33. COVID-19 Vaccine Safety First Year Findings in Adolescents

Author

Hesse, Elisabeth M., Hause, Anne, Myers, Tanya, Su, John R., Marquez, Paige, Zhang, Bicheng, Cortese, Margaret, Allen, Andrea Thames, Curtis, Christine R., Maloney, Susan A., Thompson, Deborah, Nair, Narayan, Alimchandani, Meghna, Niu, Manette, Gee, Julianne, Shay, David K., and Shimabukuro, Tom T.

Subjects
Article
Abstract

BACKGROUND/OBJECTIVES: The Food and Drug Administration (FDA) expanded Emergency Use Authorization (EUA) for use of Pfizer-BioNTech (BNT-162b2) COVID-19 vaccine to include people ages 12 years and older on May 10, 2021. Early post-authorization safety data were limited, especially for rare outcomes of concern. We describe adverse events observed during the first full year of the U.S. COVID-19 vaccination program for adolescents ages 12–17 years. METHODS: We conducted descriptive analyses using data from 2 complementary U.S. vaccine safety monitoring systems: v-safe, a voluntary smartphone-based system that monitors reactions and health impacts, and the Vaccine Adverse Event Reporting System (VAERS), the national spontaneous reporting system. We reviewed reports and calculated adverse event reporting rates using vaccine administration data. RESULTS: Among 172,032 adolescents ages 12–17 years enrolled in v-safe, most reported reactions following BNT-162b2 were mild to moderate, most frequently reported on the day after vaccination, and more common after dose 2. VAERS received 20,240 adverse event reports; 91.5% were nonserious. Among adverse events of interest, we verified 39 cases of MIS-C (1.2 cases per million vaccinations), 33 (84.6%) of which had evidence of prior SARS-CoV-2 infection; and 570 cases of myocarditis (17.7 cases per million vaccinations), most of whom (77%) reported symptom resolution at the time of report. CONCLUSIONS: During the first year BNT-162b2 was administered to adolescents ages 12–17 years, most adverse events reported to v-safe and VAERS were mild and appeared self-limited. Rates of myocarditis were lower than earlier reports. No new serious safety concerns were identified.

Published
2023

34. Preventing Emerging Infectious Diseases: A Strategy for the 21st Century: Overview of the Updated CDC Plan

Author

Binder, Suzanne, Levitt, Alexandra M., Aguilar, Judith R., Bell, David M., Cetron, Martin S., Chamberland, Mary E., Eberhard, Mark L., Gubler, Duane J., Hickson, Meredith A., Kaplan, Jonathan E., Khabbaz, Rima F., LeDuc, James W., Maloney, Susan A., Martin, William J., Mawle, Alison C., McConnon, Patrick, Meltzer, Martin I., O'Connor, Siobhán, Parkinson, Alan J., Schuchat, Anne, Solomon, Steven L., Tauxe, Robert V., Tenover, Fred C., Tsai, Theodore F., and Wainwright, Robert B.

Published
1998

36. Distinct disease mutations in DNMT3A result in a spectrum of behavioral, epigenetic, and transcriptional deficits

Author

Beard, Diana C., primary, Zhang, Xiyun, additional, Wu, Dennis Y., additional, Martin, Jenna R., additional, Hamagami, Nicole, additional, Swift, Raylynn G., additional, McCullough, Katherine B., additional, Ge, Xia, additional, Bell-Hensley, Austin, additional, Zheng, Hongjun, additional, Lawrence, Austin B., additional, Hill, Cheryl A., additional, Papouin, Thomas, additional, McAlinden, Audrey, additional, Garbow, Joel R., additional, Dougherty, Joseph D., additional, Maloney, Susan E., additional, and Gabel, Harrison W., additional

Published
2023
Full Text
View/download PDF

37. Surveillance for multisystem inflammatory syndrome in U.S. children aged 5-11 years who received Pfizer-BioNTech COVID-19 vaccine, November 2021−March 2022

Author

Cortese, Margaret M, primary, Taylor, Allan W, additional, Akinbami, Lara J, additional, Thames-Allen, Andrea, additional, Yousaf, Anna R, additional, Campbell, Angela P, additional, Maloney, Susan A, additional, Harrington, Theresa, additional, Anyalechi, E Gloria, additional, Munshi, Datta, additional, Kamidani, Satoshi, additional, Curtis, C Robinette, additional, McCormick, David W, additional, Staat, Mary A, additional, Edwards, Kathryn M, additional, Creech, C Buddy, additional, Museru, Oidda, additional, Marquez, Paige, additional, Thompson, Deborah, additional, Su, John R, additional, Schlaudecker, Elizabeth P, additional, and Broder, Karen R, additional

Published
2023
Full Text
View/download PDF

38. Building and Strengthening Infection Control Strategies to Prevent Tuberculosis — Nigeria, 2015

Author

Dokubo, E. Kainne, Odume, Bethrand, Lipke, Virginia, Muianga, Custodio, Onu, Eugene, Olutola, Ayodotun, Ukachukwu, Lucy, Igweike, Patricia, Chukwura, Nneka, Ubochioma, Emperor, Aniaku, Everistus, Ezeudu, Chinyere, Agboeze, Joseph, Iroh, Gabriel, Orji, Elvina, Godwin, Okezue, Raji, Hasiya Bello, Aboje, S.A., Osakwe, Chijioke, Debem, Henry, Bello, Mustapha, Onotu, Dennis, and Maloney, Susan

Published
2016

40. Extensive characterization of a Williams Syndrome murine model showsGtf2ird1-mediated rescue of select sensorimotor tasks, but no effect on enhanced social behavior

Author

Nygaard, Kayla R., primary, Maloney, Susan E., additional, Swift, Raylynn G., additional, McCullough, Katherine B., additional, Wagner, Rachael E., additional, Fass, Stuart B., additional, Garbett, Krassimira, additional, Mirnics, Karoly, additional, Veenstra-VanderWeele, Jeremy, additional, and Dougherty, Joseph D., additional

Published
2023
Full Text
View/download PDF

41. Characteristics and Clinical Outcomes of Children and Adolescents Aged <18 Years Hospitalized with COVID-19 — Six Hospitals, United States, July–August 2021

Author

Wanga, Valentine, Gerdes, Megan E., Shi, Dallas S., Choudhary, Rewa, Dulski, Theresa M., Hsu, Sophia, Idubor, Osatohamwen I., Webber, Bryant J., Wendel, Arthur M., Agathis, Nickolas T., Anderson, Kristi, Boyles, Tricia, Chiu, Sophia K., Click, Eleanor S., Da Silva, Juliana, Dupont, Hannah, Evans, Mary, Gold, Jeremy A.W., Haston, Julia, Logan, Pamela, Maloney, Susan A., Martinez, Marisol, Natarajan, Pavithra, Spicer, Kevin B., Swancutt, Mark, Stevens, Valerie A., Brown, Jessica, Chandra, Gyan, Light, Megan, Barr, Frederick E., Snowden, Jessica, Kociolek, Larry K., McHugh, Matthew, Wessel, David, Simpson, Joelle N., Gorman, Kathleen C., Breslin, Kristen A., DeBiasi, Roberta L., Thompson, Aaron, Kline, Mark W., Bloom, Julie A., Singh, Ila R., Dowlin, Michael, Wietecha, Mark, Schweitzer, Beth, Morris, Sapna Bamrah, Koumans, Emily H., Ko, Jean Y., Kimball, Anne A., and Siegel, David A.

Subjects
Male, Pediatric Obesity, COVID-19 Vaccines, Health (social science), Adolescent, Coinfection, Epidemiology, Health, Toxicology and Mutagenesis, Vaccination, COVID-19, Infant, General Medicine, Hospitals, United States, Hospitalization, Treatment Outcome, Health Information Management, Child, Preschool, Humans, Female, Full Report, Child
Abstract

During June 2021, the highly transmissible

Published
2021

42. Activity-dependent translation dynamically alters the proteome of the perisynaptic astrocyte process

Author

Sapkota, Darshan, primary, Kater, Mandy S.J., additional, Sakers, Kristina, additional, Nygaard, Kayla R., additional, Liu, Yating, additional, Koester, Sarah K., additional, Fass, Stuart B., additional, Lake, Allison M., additional, Khazanchi, Rohan, additional, Khankan, Rana R., additional, Krawczyk, Mitchell C., additional, Smit, August B., additional, Maloney, Susan E., additional, Verheijen, Mark H.G., additional, Zhang, Ye, additional, and Dougherty, Joseph D., additional

Published
2022
Full Text
View/download PDF

43. Factors Associated With Severe Illness in Patients Aged &lt;21 Years Hospitalized for COVID-19

Author

Choudhary, Rewa, primary, Webber, Bryant J., additional, Womack, Lindsay S., additional, Dupont, Hannah K., additional, Chiu, Sophia K., additional, Wanga, Valentine, additional, Gerdes, Megan E., additional, Hsu, Sophia, additional, Shi, Dallas S., additional, Dulski, Theresa M., additional, Idubor, Osatohamwen I., additional, Wendel, Arthur M., additional, Agathis, Nickolas T., additional, Anderson, Kristi, additional, Boyles, Tricia, additional, Click, Eleanor S., additional, Da Silva, Juliana, additional, Evans, Mary E., additional, Gold, Jeremy A.W., additional, Haston, Julia C., additional, Logan, Pamela, additional, Maloney, Susan A., additional, Martinez, Marisol, additional, Natarajan, Pavithra, additional, Spicer, Kevin B., additional, Swancutt, Mark, additional, Stevens, Valerie A., additional, Rogers-Brown, Jessica, additional, Chandra, Gyan, additional, Light, Megan, additional, Barr, Frederick E., additional, Snowden, Jessica, additional, Kociolek, Larry K., additional, McHugh, Matthew, additional, Wessel, David L., additional, Simpson, Joelle N., additional, Gorman, Kathleen C., additional, Breslin, Kristen A., additional, DeBiasi, Roberta L., additional, Thompson, Aaron, additional, Kline, Mark W., additional, Boom, Julie A., additional, Singh, Ila R., additional, Dowlin, Michael, additional, Wietecha, Mark, additional, Schweitzer, Beth, additional, Morris, Sapna Bamrah, additional, Koumans, Emilia H., additional, Ko, Jean Y., additional, Siegel, David A., additional, and Kimball, Anne A., additional

Published
2022
Full Text
View/download PDF

47. Surveillance for Multisystem Inflammatory Syndrome in US Children Aged 5–11 Years Who Received Pfizer-BioNTech COVID-19 Vaccine, November 2021 through March 2022.

Author

Cortese, Margaret M, Taylor, Allan W, Akinbami, Lara J, Thames-Allen, Andrea, Yousaf, Anna R, Campbell, Angela P, Maloney, Susan A, Harrington, Theresa A, Anyalechi, E Gloria, Munshi, Datta, Kamidani, Satoshi, Curtis, C Robinette, McCormick, David W, Staat, Mary A, Edwards, Kathryn M, Creech, C Buddy, Museru, Oidda, Marquez, Paige, Thompson, Deborah, and Su, John R

Subjects
MULTISYSTEM inflammatory syndrome in children, SARS-CoV-2, COVID-19 vaccines, COVID-19, CORONAVIRUS diseases
Abstract

Multisystem inflammatory syndrome in children (MIS-C) is a complication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection; in the United States, reporting of MIS-C after coronavirus disease 2019 (COVID-19) vaccination is required for vaccine safety monitoring. Pfizer-BioNTech COVID-19 vaccine was authorized for children aged 5−11 years on 29 October 2021. Covering a period when approximately 7 million children received vaccine, surveillance for MIS-C ≤ 90 days postvaccination using passive systems identified 58 children with MIS-C and laboratory evidence of past/recent SARS-CoV-2 infection, and 4 without evidence. During a period with extensive SARS-CoV-2 circulation, MIS-C illness in children after COVID-19 vaccination who lacked evidence of SARS-CoV-2 infection was rare (<1 per million vaccinated children). [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results